✦ LIBER ✦

Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes

✍ Scribed by Stéphane Dalle; Rémy Burcelin; Pierre Gourdy

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of Type 2 diabetes mellitus wi

✍ Holst, Jens Juul 📂 Article 📅 2004 🏛 Informa plc 🌐 English ⚖ 147 KB

The Place of GLP-1–Based Therapy in Diab

✍ Eckerle Mize, Dara L.; Salehi, Marzieh 📂 Article 📅 2013 🏛 Current Science Inc. 🌐 English ⚖ 255 KB

Evaluating Second-Line Treatment Options

✍ Boland, C. L.; DeGeeter, M.; Nuzum, D. S.; Tzefos, M. 📂 Article 📅 2013 🏛 Harvey Whitney Books Company 🌐 English ⚖ 321 KB

The safety and tolerability of GLP-1 rec

✍ D. Russell-Jones 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB

Pharmacokinetics, safety, and efficacy o

✍ Giorda, Carlo B.; Nada, Elisa; Tartaglino, Barbara 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 336 KB

DPP-4 inhibitors and GLP-1 analogues: fo

✍ S. Halimi 📂 Article 📅 2008 🏛 Masson Editeur 🌐 French ⚖ 451 KB